It is almost 50 years since MEA was first developed, however, the power of this technology in toxicology testing has only just been realised due to the introduction of the multi-well MEA allowing for its utility in high throughput analysis.
In this whitepaper, we focus on:
the current challenges within the pharmaceutical industry in terms of toxicology prediction
how companies are addressing these challenges using human relevant cell-based models
an in-depth evaluation of microelectrode array (MEA) and its key role in in vitro cardiotoxicity and neurotoxicity toxicology testing
Read our whitepaper to learn more!
Sounds interesting? Enter your details below to continue reading…
Join our community
Discover the exclusive benefits on offer if you join our community.